Journal
International Journal of Radiation Oncology, Biology, Physics
Publication Date
5-1-2022
Volume
113
Issue
1
First Page
66
Last Page
76
Document Type
Open Access Publication
DOI
10.1016/j.ijrobp.2021.09.034
Rights and Permissions
Tward J, Lenz L, Flake DD II,, Rajamani S, Yonover P, Olsson C, Kapoor DA, Mantz C, Liauw SL, Antic T, Fabrizio M, Salzstein D, Shore N, Albertson D, Henderson J, Lee SP, Gay HA, Michalski J, Hung A, Raben D, Garraway I, Lewis MS, Nguyen PL, Marshall DT, Brawer MK, Stone S, Cohen T. The clinical cell-cycle Risk (CCR) score is associated with metastasis after radiation therapy and provides guidance on when to forgo combined androgen deprivation therapy with dose-escalated radiation. Int J Radiat Oncol Biol Phys. 2022 May 1;113(1):66-76. doi: 10.1016/j.ijrobp.2021.09.034. Epub 2021 Oct 3. Erratum in: Int J Radiat Oncol Biol Phys. 2023 Feb 1;115(2):543. Copyright 2021 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Recommended Citation
Tward, Jonathan; Gay, Hiram A.; Michalski, Jeff; and et al., "The clinical cell-cycle risk (CCR) score is associated with metastasis after radiation therapy and provides guidance on when to forgo combined androgen deprivation therapy with dose-escalated radiation." International Journal of Radiation Oncology, Biology, Physics. 113, 1. 66 - 76. (2022).
https://digitalcommons.wustl.edu/oa_4/1898
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
